Duopharma Biotech Berhad Posts Commendable Q4 2019 Results with Gross Profit of RM52.19 million on revenue of RM137.76million
KUALA LUMPUR, 13 February 2020 – In an announcement to Bursa Malaysia this evening,
Duopharma Biotech Berhad (formerly known as CCM Duopharma Biotech Berhad) (“Duopharma
Biotech” or “Company”) announced a commendable set of unaudited financial results to close off a
strong performance in 2019 with yearly net profit increasing 16 percent to touch RM55.27 million
(2018: RM47.64 million) on higher revenue of RM576.46 million (2018: RM498.72 million).